Kevin Otipoby
About Kevin Otipoby
Kevin Otipoby Chief Research Officer
Kevin Otipoby serves as the Chief Research Officer, bringing more than 25 years of experience in the field of immunology from both industry and academia. His extensive career focuses on understanding lymphocyte activation and developing therapeutics to modulate lymphocyte activity. Otipoby has played a pivotal role in various leading pharmaceutical companies, contributing significantly to the discovery and development of novel treatments for autoimmune diseases.
Kevin Otipoby Education and Expertise
Kevin Otipoby graduated magna cum laude from Washington University in St. Louis with a bachelor's degree in Molecular Biology and Biochemistry. He furthered his education by obtaining a Ph.D. in Immunology from the University of Washington in Seattle. Otipoby completed his post-doctoral training in Klaus Rajewsky's lab at Harvard University. His educational background and research expertise make him an influential figure in the field of immunology.
Kevin Otipoby Background in Immunology
Kevin Otipoby's career in immunology includes significant roles in major pharmaceutical companies. At Pandion Therapeutics, Otipoby was the second employee and led their Immunology and Biomarker groups. He built a successful interdisciplinary discovery team, contributing to Pandion's acquisition by Merck in 2021 for $1.85 billion. His work at Abbvie involved leading the biology efforts to discover a small molecule GPCR agonist with colon-restricted activity for treating IBD. At Biogen, Otipoby focused on discovering and developing small molecule inhibitors of BTK for treating autoimmune diseases and worked on a biologics program targeting long-lived plasma cells.
Kevin Otipoby Achievements
Kevin Otipoby has achieved notable milestones throughout his career. He played a crucial role at Pandion Therapeutics in forming a successful interdisciplinary discovery team, which eventually led to the company's $1.85 billion acquisition by Merck. At Abbvie, he contributed to the discovery of a small molecule GPCR agonist for IBD treatment. At Biogen, Otipoby led efforts to develop small molecule inhibitors of BTK for multiple autoimmune diseases and initiated a biologics program targeting long-lived plasma cells. Otipoby also serves on the scientific advisory board of Eurofins Scientific, leveraging his extensive expertise in the field.